School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Microbiol Res. 2024 Jul;284:127675. doi: 10.1016/j.micres.2024.127675. Epub 2024 Mar 7.
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis), mainly transmitted through droplets to infect the lungs, and seriously affecting patients' health and quality of life. Clinically, anti-TB drugs often entail side effects and lack efficacy against resistant strains. Thus, the exploration and development of novel targeted anti-TB medications are imperative. Currently, protein-protein interactions (PPIs) offer novel avenues for anti-TB drug development, and the study of targeted modulators of PPIs in M. tuberculosis has become a prominent research focus. Furthermore, a comprehensive PPI network has been constructed using computational methods and bioinformatics tools. This network allows for a more in-depth analysis of the structural biology of PPIs and furnishes essential insights for the development of targeted small-molecule modulators. Furthermore, this article provides a detailed overview of the research progress and regulatory mechanisms of PPI modulators in M. tuberculosis, the causative agent of TB. Additionally, it summarizes potential targets for anti-TB drugs and discusses the prospects of existing PPI modulators.
结核病（TB）是一种由结核分枝杆菌（M. tuberculosis）引起的慢性传染病，主要通过飞沫传播感染肺部，严重影响患者的健康和生活质量。临床上，抗结核药物往往存在副作用，且对耐药菌株缺乏疗效。因此，探索和开发新型靶向抗结核药物势在必行。目前，蛋白质-蛋白质相互作用（PPIs）为抗结核药物的开发提供了新的途径，针对结核分枝杆菌中 PPI 的靶向调节剂的研究已成为一个突出的研究重点。此外，还使用计算方法和生物信息学工具构建了一个全面的 PPI 网络。该网络允许更深入地分析 PPI 的结构生物学，并为开发靶向小分子调节剂提供必要的见解。此外，本文详细概述了结核分枝杆菌（TB 的病原体）中 PPI 调节剂的研究进展和调控机制。此外，还总结了抗结核药物的潜在靶点，并讨论了现有 PPI 调节剂的前景。
